Using ADCT in clinical studies

Atopic Dermatitis Control Tool (ADCT) has been scientifically validated to assess atopic dermatitis control status in adult1 and adolescent patients (12 years and older). ADCT can indicate changes in control status within a patient over a time period of several months.2

Why assess long-term control of AD in clinical studies?

The Harmonising Outcome Measures for Eczema (HOME) initiative identified long-term control as one of the four core outcome domains that should be measured and reported in all atopic dermatitis trials:

  • HOME has recommended ADCT as a core outcome instrument for measuring long-term control of atopic dermatitis in clinical trials3

  • HOME encourages the use of standardised measures of core outcome domains to enable trials to be compared and combined in meta-analyses, thus enabling evidence-based analysis of clinical data3

Is ADCT free of charge?

Yes, ADCT is made available on an Open Access scheme. If you are planning to use ADCT in a clinical study, please use the following link to request the correct version of ADCT and the copyright from MAPI Research Trust:

https://eprovide.mapi-trust.org/instruments/atopic-dermatitis-control-tool

You will be asked to complete a request form describing the intended use of the tool. The information provided with this form helps to ensure that ADCT is used in the context and with the standards it has been designed and validated for.

Footnotes
  • Pariser DM, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT).
    Curr Med Res Opin (2019) doi:10.1080/03007995.2019.1699516
  • Simpson E, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis.
    BMC Dermatol 19, 15 (2019) doi:10.1186/s12895-019-0095-3
  • http://www.homeforeczema.org.  Accessed November 2019